EOFlow Co's United States subsidiary signs contract with Zihipp Limited
29 December 2021 -

EOFlow Co. Ltd. (KOSDAQ: 294090), a South Korea-based supplier of wearable drug delivery solutions, announced on Tuesday that its wholly owned US subsidiary, EOFlow Inc, has signed a contract with Zihipp Limited, a United Kingdom-based biotech company and a spin out from Imperial College London, to set up a joint venture in the United States.

The new joint venture is named SanPlena and the companies say that it is to concentrate on developing a range of gut-hormone analogues that promise rapid and dramatic weight loss without the common side effects seen with other such agents delivered through daily or weekly injection.

EOFlow is to offer an initial funding and its EOPatch wearable drug delivery platform, while Zihipp is to provide its proprietary peptide analogues and clinical support for SanPlena. Jesse J Kim, EOFlow's founding CEO is the founding CEO of SanPlena, while the rest of the executive team will be rounded out by senior staff from both Zihipp and EOFlow.